NCT03921021: A reported trial by Weill Medical College of Cornell University
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03921021 |
|---|---|
| Title | Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 9, 2019 |
| Completion date | June 20, 2023 |
| Required reporting date | June 19, 2024, midnight |
| Actual reporting date | April 22, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |